SLC5A2 and hydrops fetalis: In 2017, the Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) trial retrospectively compared the effects of SGLT-2 inhibitors in cardiovascular morbidity and mortality against other antidiabetic factors, and it showed a reduction of 39% in hospitalizations for HF-adverse events in patients treated with SGLT-2 inhibitors [124].